LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

Inicio・Lista de Acciones・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Abierto

1.77 -5.85

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.76

Máximo

1.88

Métricas clave
By Trading Economics
Ingresos	23T 23T
Empleados	8
EBITDA	1.1T 1.1T

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+194.12% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-166M 134M
Apertura anterior	7.62
Cierre anterior	1.77

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.9 / 2.65 Soporte y Resistencia

Aldeyra Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 mar 2026, 13:34 UTC

Principales Movimientos del Mercado

Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns

16 dic 2025, 11:43 UTC

Principales Movimientos del Mercado

Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

3 abr 2025, 22:40 UTC

Principales Movimientos del Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

Comparación entre iguales

Cambio de precio

Aldeyra Therapeutics Inc previsión

Precio Objetivo

By TipRanks

194.12% repunte

Estimación a 12 Meses

Media 5.5 USD 194.12%

Máximo 9 USD

Mínimo 2 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Aldeyra Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Aldeyra Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.9 / 2.65Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.